Treatment with RAF inhibitors such as vemurafenib cause the development of cutaneous squamous cell carcinomas (cSCC) or keratoacanthomas (KA) as a side-effect in 18-30% of patients. It is known that RAF inhibitors activate the MAPK pathway and stimulate growth of RAS mutated cells, possibly accounting for up to 60% of cSCC or KA lesions with RAS mutations, but other contributing events are obscure. To identify such events, we evaluated tumors from patients treated with vemurafenib for the presence of HPV DNA and identified 13% to be positive. Using a transgenic murine model of HPV-driven cSCC (K14-HPV16 mice), we conducted a functional test to determine whether administration of RAF inhibitors could promote cSCC in HPV-infected tissues. Vemurafenib treatment elevated MAPK markers and increased cSCC incidence from 22% to 70% in this model. Furthermore, 55% of the cSCCs arising in vemurafenib-treated mice exhibited a wild-type Ras genotype, consistent with the frequency observed in human patients. Our results argue that HPV cooperates with vemurafenib to promote tumorigenesis, in either the presence or absence of RAS mutations.
Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors
vemurafenib, demonstrated improved survival and dramatic reduction in tumor burden (2, 3) . Among the most common side effects is the emergence of non-melanocytic cutaneous tumors, including squamous cell carcinomas (cSCC), keratoacanthomas (KA), and verrucous papillomas (2) (3) (4) (5) . Pre-clinical data demonstrates that RAF inhibitors paradoxically stimulate ERK phosphorylation in RAS mutated cancer cells (6-9) through allosteric and catalytic mechanisms that relieve the auto-inhibition of wildtype RAF kinase (10) . It is therefore hypothesized that paradoxical activation of the MAPK pathway induces cSCC and KA tumorigenesis in patients treated with RAF inhibitors.
Several groups have described the genetics of KA and cSCC induced by RAF inhibitors. Most notably 18-60% of the clinical biopsies harbor a RAS mutation (11) (12) (13) , and treatment with a vemurafenib analogue (PLX-4720) also decreased tumor latency in a mouse model for Hras driven cSCC (13) . However, 40-82%
of KAs and cSCCs from RAF inhibitor treated patients are RAS wild-type, suggesting that accelerated oncogenesis of RAS mutated cells is not the only mechanism involved. Among the other mutated genes identified in cutaneous lesions from RAF inhibitor treated patients are FGFR3, TGFBR1, MYC, PIK3CA, and tumor suppressors TP53, CDKN2A, and VHL (4, 11) . While FGFR3 and TGFBR1 mutations may lead to RAS activation and therefore hyperactivate the MAPK pathway in response to RAF inhibitors, it is unclear how critical RAS-activating oncogenes are to vemurafenib-induced cSCC. Furthermore, the role of other drivers, such as infectious agents like HPV, have not been carefully examined. Therefore, we used a transgenic mouse model that expresses the HPV16 early genes from the keratin 14 promoter (K14-HPV16) to evaluate the relationship between vemurafenib-treatment and HPV in driving cSCC (14) .
Materials and Methods
HPV screening of clinical biopsies. Cellular DNA was extracted from biopsies of cutaneous lesions or normal skin. HPV types were identified using consensus FAP59/64 primers as described (15) . Samples were also analyzed by a nested PCR method with two sets of degenerate primers (CP65/CP70 and CP66/CP69) located in the L1 open reading frame as described (16 Tissue culture. Proliferation of A375, SW620 (from ATCC), and GTL-16 cells (from S. Giordano, Cancer
Research and Treatment, Turin, Italy) was measured by Cell Titer-Glo (Promega) and Rat-1 cells (from J.
Gorski, University of Wisconsin) were grown in soft agar suspension. pERK quantification by sandwich immunoassay (MSD). All cell lines were routinely inspected for morphological changes and tested mycoplasma negative. A375, SW620 and GTL-16 were also inspected for DNA copy number and gene expression changes as previously described (17 Ras genotyping of mouse K14-HPV16 cSCC. Genomic DNA was collected from 9 cSCCs and 1 non-tumor skin sample from untreated K14-HPV16 mice, and 9 cSCCs and 1 non-tumor skin sample from K14-HPV16 mice treated with 60 mg/kg vemurafenib. 100bp x 2 paired end sequencing (Illumina) was performed after mouse exome capture (Agilent). Sequences were aligned to the MM9 genome using 6 bwa v0.6.1 (18) and processed according to GATK v2 (19) best practices by running the IndelRealigner, MarkDuplicates, and TableRecalibration tools per sample, and using dbSNP (20) Figure 1D ), demonstrating that vemurafenib treatment is sufficient to activate the MAPK pathway and promote a transformation phenotype. However, the magnitude of activation may be dependent upon the underlying genetics, and vemurafenib induced activation appears to be particularly exaggerated in RAS mutated cells.
A subset of cutaneous lesions from vemurafenib treated patients are HPV positive and RAS wild-type
Given these observations, we hypothesized that paradoxical activation of the MAPK pathway by RAF inhibitor treatment may promote cSCC tumorigenesis only in the presence of pre-existing genetic lesions. Several common tumor suppressor mutations have been identified in cSCCs from patients treated with RAF inhibitors including TP53, CDKN2A, and VHL (4, 11) . In addition to host mutations, the contribution of viral oncogenes has also been implicated in cSCC tumorigenesis. The majority of nonmelanocytic lesions occurring in vemurafenib-treated patients include several benign skin lesions with strong associations with HPV, including venereal warts and verrucous papillomas (5), which strongly implicates a role for HPV. Although the frequency is low, expression of HPV capsid protein has been observed in one cSCC from a patient treated with the RAF inhibitor dabrafenib (22) , and HPV DNA was observed in a separate case study (23) .
To determine if an HPV infection may contribute to cutaneous tumor initiation in patients treated with vemurafenib, 62 benign or malignant cutaneous lesions from 44 patients were collected and tested for presence of HPV DNA. Eight of the lesions (13%) tested positive for one of 6 HPV types (Figure 2 ), indicating that HPV may contribute in a subset of cases. Because HPV can also be found on normal skin and may be considered commensal with human tissue, we tested several tumors from the same patients including normal skin samples when possible. In four cases, patients with HPV-positive tumors also had additional skin tumors or normal skin samples that were HPV negative. In one patient, two To test for the presence of Ras ocnogenes, cSCCs were collected from both vemurafenib treated and untreated K14-HPV16 mice and genomic exons were sequenced. Somewhat surprisingly, 100% (9/9) of vemurafenib naïve tumors sequenced carried an activating Ras mutation, 8 of which were Kras mutated, and 1 Hras (Q61L) mutated ( Figure 3D ), suggesting that a Ras oncogene is required for cSCC in this model. However, only 44% (4/9) of the cSCCs from vemurafenib treated mice were Ras mutated ( Figure   3D ), suggesting that the increase in cSCC frequency is due to an increase of Ras wild-type tumors.
Tumors from both vehicle and vemurafenib treated mice were also stained for ERK phosphorylation, and Figure 5C ), suggesting the higher response rate is due to sustained MEK inhibition. Together, these results strongly indicate that MEK activity is required for cSCC tumor maintenance.
Discussion
While it is known that RAF inhibitors accelerate RAS mutant tumor growth, it is unclear why roughly 40-80% of cSCCs from patients treated with vemurafenib are RAS wild-type (11, 13) . In the present study vemurafenib not only increased the incidence and accelerated tumorigenesis, but also clearly induced Ras wild-type cSCC in K14-HPV16 mice (Figure 3C-D) . This suggests that vemurafenib is required for 
is not only required for initiation, but also for cSCC maintenance. However, it is important to note that vemurafenib induced cSCC was only observed in K14-HPV16 transgenic mice, and not in HPV negative, non-transgenic littermates. Therefore, treatment with vemurafenib alone, while sufficient to paradoxically activate the MAPK pathway in mouse dermis, and necessary for Ras wild-type tumorigenesis in K14-HPV16 mice, was not sufficient to initiate cSCC. Clearly loss of tumor suppressor function is a minimum requirement for vemurafenib-induced cSCC.
HPV has been linked to cancer progression for decades due to the transformation potential of HPV oncogenes. HPV has been observed in both mucosal and cutaneous tumors, though the mechanism of oncogenesis likely differs. Cervical and head & neck cancers are clearly linked to alpha-HPV genotypes, which exhibit mucosal tropism, while beta-HPVs are more frequently associated with cutaneous disease.
Although the mechanism of transformation for beta-HPV is not fully understood, transgenic mouse studies demonstrate that keratinocyte specific expression of either the HPV8 (beta-HPV) or HPV16 (alpha-HPV) genes can promote cSCC in the FVB/N background (14, 26) . Additionally, while expression of HPV transcripts can be seen in established cervical cancers, expression of HPV genes is often undetectable even in cSCC from HPV positive patients (27) , indicating that HPV does not play an active role in cSCC tumor maintenance. Data presented here demonstrate that a subsequent Ras mutation is also required for HPV16 driven tumorigenesis in the K14-HPV16 model ( Figure 3D ). These data are consistent with the function of HPV16 E6 and E7 oncogenes, which target P53 and pRB tumor suppressors to prevent the DNA damage response, and implicate HPV in cSCC initiation rather than tumor maintenance. Although it is unclear if beta-HPV initiate transformation through a similar mechanism, 27% (6/22) of cSCC from K14-HPV8 transgenic mice develop a spontaneous Hras mutation (28), compared to 11% (1/9) in the HPV16 model ( Figure 3D ). Further investigation in beta-HPV models may therefore reveal common mechanisms of oncogenesis. 
